Dotmatics Acquired by Siemens for $5.1 Billion to Accelerate AI Innovation in Life Sciences
Siemens AG is acquiring Dotmatics for $5.1 billion to integrate Dotmatics’ scientific R&D software with Siemens’ AI-powered Digital Twin technologies, aiming to accelerate innovation in life sciences research and development and enhance Siemens’ AI-driven product lifecycle management portfolio as part of its ONE Tech Company growth strategy.
- Siemens AG will acquire Dotmatics from global software investor Insight Partners for $5.1 billion.
- The acquisition accelerates Dotmatics’ mission to connect scientific discovery to delivery, expanding global scale and reach.
- Unlocks new opportunities to combine Dotmatics’ R&D software with Siemens’ AI-powered Digital Twin technologies.
- Represents a strong validation of Dotmatics’ growth, innovation, and leadership in scientific software.
April 2, 2025 - Boston – Dotmatics®, a leading provider of scientific software that provides end-to-end solutions to connect science, data, and decision making for life sciences R&D, announced it has signed a definitive agreement to be acquired by Siemens AG for $5.1 billion.
“Following an exciting journey with Insight Partners, where Dotmatics achieved remarkable growth and portfolio expansion, we are thrilled to announce our new chapter with Siemens,” said Thomas Swalla, CEO of Dotmatics. “Combining our next-generation scientific intelligence platform and industry-leading scientific applications together with Siemens' Digital Twin and AI capabilities, we’ll drive a new wave of innovation in life sciences R&D. Together, we'll accelerate innovation cycles for our customers and help scientists make breakthrough discoveries faster than ever before shaping the future of scientific innovation.”
“By acquiring Dotmatics, we’re strategically strengthening our position in life sciences and creating a world-leading AI-powered PLM software portfolio as part of Siemens Xcelerator. Artificial Intelligence has emerged as a transformative force across various industries, and its application in life sciences is becoming increasingly important,” said Roland Busch, President and CEO of Siemens AG. “The Dotmatics acquisition is part of our ONE Tech Company growth program, enhancing our leading position in industrial software and helping our customers to innovate even faster.”
The acquisition will strengthen Siemens’ and Dotmatics' ability to empower scientists through advanced software solutions that facilitate next-generation collaboration, contextualize complex data, and accelerate research using AI. As part of Siemens, Dotmatics will benefit from expanded global resources, robust infrastructure, and a broader customer network, significantly advancing its mission to revolutionize scientific discovery for a healthier, cleaner, and safer world.
Life sciences stands as one of the most rapidly evolving and innovation-rich sectors globally. The combination of Siemens' extensive manufacturing expertise, industrial simulation capabilities, and AI strengths, with Dotmatics' complementary scientific applications, will establish a first-of-its-kind end-to-end digital thread to seamlessly connect research data through to production in the life sciences industry.
“When we first invested in what is now Dotmatics in 2017, we recognized the enormous potential of the platform being developed and the impact the company’s technology would have on life sciences R&D,” said Jared Rosen, Managing Director at Insight Partners. “It has been a privilege to collaborate closely with Thomas and the Dotmatics leadership team, actively supporting 14 strategic acquisitions and providing resources through our Onsite platform to fuel their impressive growth. The transition of Dotmatics from Insight Partners to Siemens represents a logical next step, empowering Dotmatics to further advance its mission of accelerating innovation within life sciences. This acquisition opens new avenues to seamlessly connect scientific discovery with manufacturing execution, enabling scientific R&D organizations to rapidly and confidently transition breakthroughs from molecule to market.”
Approvals & Timing
The transaction is expected to close following customary regulatory approvals and other closing conditions.
Advisors
Evercore served as the exclusive financial advisor and Willkie Farr & Gallagher LLP served as legal advisor to Dotmatics on the transaction.
About Dotmatics
Dotmatics is a leader in R&D scientific software connecting science, data, and decision-making. Its enterprise R&D platform and applications, including GraphPad Prism, SnapGene and Geneious, drive efficiency and accelerate innovation. More than 2 million scientists and 14,000 customers trust Dotmatics to help them create a healthier, cleaner, safer world. Dotmatics is a global team of more than 800 people dedicated to supporting its customers in over 180 countries. The company is headquartered in Boston, with 14 offices and R&D teams located around the world. Learn more about Dotmatics at www.dotmatics.com.
About Siemens
Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company’s purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. In fiscal 2024, which ended on September 30, 2024, the Siemens Group generated revenue of €75.9 billion and net income of €9.0 billion. As of September 30, 2024, the company employed around 312,000 people worldwide on the basis of continuing operations. Further information is available at www.siemens.com.
About Insight Partners
Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of September 30, 2024, the firm has over $90B in regulatory assets under management. Insight Partners has invested in more than 800 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has offices in London, Tel Aviv, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com.
Forward Looking Statements
This press release contains forward-looking statements that do not relate solely to historical or current facts, such as statements regarding our expectations, intentions or strategies regarding the future. The forward-looking statements are based on management’s beliefs, as well as assumptions made by, and information currently available to, Dotmatics. Because such statements are based on expectations as to future operating results they are not statements of fact. Actual results may differ materially from those projected and are subject to a number of known and unknown risks and uncertainties. The press release speaks only as of the date the statements are first published. Dotmatics undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media Contacts
Cory Edwards
Vice President, Corporate Communications
Dotmatics
cory.edwards@dotmatics.com
801-386-1960
Nikki Parker
SVP, Marketing & Communications
Insight Partners
nparker@insightpartners.com
Related
Meet Dotmatics: Powering Life Sciences Breakthroughs with AI
The International Business Times article highlights how Dotmatics leverages AI-powered software to accelerate research, transform drug discovery, genomics, and data integration, and drive innovation for life sciences organizations across the APAC region.
Addressing Inefficient R&D Workflows
The blog discusses how legacy, fragmented R&D systems hinder innovation in complex, multi-domain scientific research by creating silos and inefficiencies, and presents Dotmatics’ unifying platform as a comprehensive solution that integrates diverse tools, data, and teams to enable smarter collaboration, governed data use, and AI-driven automation for faster, more rigorous innovation.
Dotmatics Set to Transform the Future of Scientific Software and Data Management
Dotmatics, formed from the merger of Insightful Science and Dotmatics, is launching a powerful integrated enterprise R&D platform combining its scientific software with popular applications like SnapGene, Geneious, and GraphPad Prism to address complex data challenges and accelerate scientific research and collaboration for over two million scientists and 10,000 customers worldwide.
The Rise of Biotech: Why Smaller Companies Are Outpacing Big Pharma on Innovation
Smaller biotech companies are increasingly outpacing big pharmaceutical firms in new molecular entity approvals due to their greater agility, willingness to take risks, and freedom to innovate despite funding challenges, with over half of upcoming blockbuster drug launches expected from first-time launchers who face higher risks but also potential for significant success.
Dotmatics Appoints Mike McKee as President and CEO
Dotmatics Ltd has appointed experienced technology CEO Mike McKee as its new President to accelerate the company's growth, scale its global team, double R&D investments, and lead integration efforts within Insightful Science's portfolio, succeeding founder Stephen Gallagher who will focus on strategic growth initiatives.
USA Today: How Dotmatics is Powering the AI-Driven Future of Drug Discovery
The USA Today article highlights Dotmatics as a pivotal force in the AI-driven transformation of drug discovery, emphasizing its cloud-based data management platform and the launch of Luma, a multimodal drug discovery platform that enhances scientific innovation and R&D efficiency.